Sixth Issue, Series Two Biosimilars in Oncology

Understanding the Value of Biosimilars in Oncology

We all go to our local pharmacy to get prescriptions filled for ourselves or a loved one. We usually notice, primarily based on the copayment, whether the prescription drug we are getting is a trade name we may see in a television commercial or it is a generic drug. How? [ Read More ]

Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG

The Role of Biosimilars in Oncology: A Nurse’s Perspective

Cindy is a 52-year-old female with non-Hodgkin lymphoma. She plans to undergo an autologous hematopoietic stem cell transplant (HSCT). When discussing the risks associated with HSCT, the oncologist warns Cindy that her white blood cells (WBCs) will become critically low as a result of high-dose chemotherapy. The low WBCs will [ Read More ]

Beth Faiman, RN, MSN, APRN, BC, AOCN

The Role of Biosimilars in Oncology: A Pharmacist’s Perspective

CJ is a 62-year-old female beginning chemotherapy with doxorubicin and cyclophosphamide for stage III breast cancer. To minimize the risk of neutropenia-associated complications, it is planned for CJ to return to the clinic daily following chemotherapy for injections of a colony-stimulating factor (CSF) until her absolute neutrophil count exceeds 10,000 [ Read More ]

Steve Stricker, PharmD, MS, BCOP

The Role of Biosimilars in Oncology: A Physician’s Perspective

In April 2011, the National Comprehensive Cancer Network (NCCN) convened a summit of key stakeholders regarding the issues surrounding biosimilars in oncology care. The working group subsequently published a sentinel white paper outlining the regulatory, scientific, and patient safety issues surrounding the development and expansion of biosimilars in oncology care.1 [ Read More ]

Jeffery A. Meyerhardt, MD, MPH